- Telehealth Visits
- Insurance plan information
Katy K. Tsai, MD
Cutaneous (Skin) Medical Oncology- Telehealth Visits
- Insurance plan information
Katy K. Tsai, MD
Cutaneous (Skin) Medical Oncology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Katy K. Tsai is a medical oncologist who specializes in treating melanoma and other skin cancers.
In addition to caring for patients, Tsai conducts clinical trials with two of her colleagues in cutaneous oncology, Dr. Adil Daud and Dr. Alain Algazi, seeking new and better therapies for patients with advanced melanoma or head and neck cancers. She also has a long-standing research interest in quality of life and outcomes for patients receiving immunotherapy.
Tsai graduated with a degree in comparative literature from Brown University before earning her medical degree from Brown. She completed a residency in internal medicine at the University of North Carolina at Chapel Hill, followed by a fellowship in medical oncology at UCSF, where she served as chief fellow.
Tsai is a member of the American Society of Clinical Oncology. She was born in Taiwan and raised in Toronto.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Oncology, University of CA at San Francisco - Hema/Onc GME
Residency
- Internal Medicine, University of North Carolina Schl of Medicine GME
Internship
- Internal Medicine, University of North Carolina Schl of Medicine GME
Degree
- MD, Brown University School of Medicine
My expertise
Specialties
Locations
My research
Clinical trials
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous MalignanciesOpens in a new window
Recruiting
The effect of RP1 on objective response rate (ORR) as assessed by Independnet Central Review (ICR) per Response Evaluation Criteria in Solid Tumors version…Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaOpens in a new window
Recruiting
Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be…Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid MalignanciesOpens in a new window
Recruiting
To identify dose limiting toxicities [DLT] with GIM-122Safety and Tolerability Study of GIM-531 in Advanced Solid TumorsOpens in a new window
Recruiting
To assess incidence and severity of AE / SAEs and tolerability assessed by CTCAE grading
Publications
Showing 1-6 of 50 reviews
- December 29, 20255 out of 5 Stars
Consistent and considerate care
- December 18, 20255 out of 5 Stars
Dr Tsai was a pleasure to meet in person. She's very knowledgeable and explained the potential treatment roadmap and opportunities with empathy.
- December 18, 20255 out of 5 Stars
Very pleasant visit.
- December 14, 20255 out of 5 Stars
We feel extremely fortunate to be able to confer with Doctor Tsai, frankly we would be lost without her.
- December 4, 20255 out of 5 Stars
My care team is stellar! I completely trust them with their care of me. I am so grateful to have Dr. Tsai and her excellent staff on my team.
- December 4, 20255 out of 5 Stars
My doctor has so much experience and uses it to help all her patients she knows what is going on and helps me through it
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.